Biopharmaceutical manufacturers should consider the advantages of single-use technology in mitigating the risk of Mycoplasma contamination, according to Parker Bioscience Filtration.
Parker Bioscience Filtration, which is part of Parker Hannifin - the world's leading diversified manufacturer of motion and control technologies and systems - will be offering guidance on how to implement a holistic approach to the prevention of Mycoplasma contamination in a forthcoming webinar.
The Prevention and Control of Mycoplasma Contamination in Bioprocessing Webinar, which will take place on January 15, will examine the sources of Mycoplasma contamination, the risks they pose and how they can be tackled by the application of industry best practice.
The webinar, which will be presented by Guy Matthews, Global Market Development Manager at Parker Bioscience Filtration and Dr Carolyn Heslop, Technical Support Group Team Leader at Parker Bioscience Filtration, is set to help biopharmaceutical manufacturers understand the benefits of single-use automation in preventing contamination – and how automation can be applied in practice.
Parker Bioscience Filtration, which has sites in Birtley, UK and Oxnard, California, designs, supplies and delivers whole systems for both upstream and downstream pharmaceutical and biopharmaceutical manufacturing.
It supports companies in improving process control, efficiency and security throughout their production and packaging processes, and provides integrated bioprocessing solutions that speed up development times, increase efficiency and safety, and enable reproducible quality. Incorporating SciLog® and domnick hunter, Parker Bioscience Filtration combines filtration, single-use fluid-handling systems and sensors into automated single-use solutions.
Guy Matthews, Global Market Development Manager at Parker Bioscience Filtration, said: “The consequences of a Mycoplasma contamination can be extremely severe for a biopharmaceutical manufacturer. In the short term, a manufacturer may face costly unplanned downtime and lost batches, resulting in the supply of pharmaceutical products to patients being affected.
“In the long term, companies may face financial consequences through a loss of confidence and a resulting decline in stock value.
“It is therefore vital that biopharmaceutical manufacturers take steps to mitigate the risk of Mycoplasma contamination – and understand how to apply process control strategies to their own facility or processes.”
Dr Carolyn Heslop, Technical Support Group Team Leader at Parker Bioscience Filtration, added: “Personnel working across the biopharmaceutical manufacturing industry – including purification scientists, operations managers, facilities managers and quality assurance managers – all have a part to play in combating the risk of Mycoplasma contamination. This webinar will provide valuable advice on how to approach this challenge, drawn from our in-depth knowledge of best practice and technology.”
The webinar will take place on January 15, 2018 at 3pm London time/10am New York time. To register visit https://www.business-review-webinars.com/webinar/Pharma/Prevention_and_control_of_Mycoplasma_contamination_in_bioprocessing-Gck9LTmr.
For more information, visit www.parker.com/bioscience.
About Parker Hannifin
Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. For more information, visit www.parker.com or @parkerhannifin.
SOURCE: Parker Bioscience